KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Taxes (2021 - 2024)

Moderna (MRNA) has disclosed Current Taxes for 4 consecutive years, with $4.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Current Taxes fell 92.86% to $4.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $4.0 million, a 92.86% decrease, with the full-year FY2023 number at $63.0 million, up 31.25% from a year prior.
  • Current Taxes was $4.0 million for Q3 2024 at Moderna, down from $7.0 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $1.6 billion in Q1 2022 to a low of $4.0 million in Q3 2024.
  • A 4-year average of $291.6 million and a median of $63.0 million in 2023 define the central range for Current Taxes.
  • Biggest YoY gain for Current Taxes was 31.25% in 2023; the steepest drop was 95.85% in 2023.
  • Moderna's Current Taxes stood at $876.0 million in 2021, then plummeted by 94.52% to $48.0 million in 2022, then skyrocketed by 31.25% to $63.0 million in 2023, then tumbled by 93.65% to $4.0 million in 2024.
  • Per Business Quant, the three most recent readings for MRNA's Current Taxes are $4.0 million (Q3 2024), $7.0 million (Q2 2024), and $52.0 million (Q1 2024).